Presymptomatic microRNA-based biomarker signatures for the prognosis of localized radiation injury in mice
PLOS One · 2025
DOI: 10.1371/journal.pone.0329737 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Lucie Ancel und 10 weiteren Autor:innen. Beteiligte Einrichtung: Autorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE/SERAMED/LRAcc, Fontenay-aux-Roses, France. Hauptthemen laut MEDLINE: MicroRNAs, Biomarkers, Radiation Injuries, Radiation Injuries, Experimental. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Electricité de France, Agence Nationale de la Recherche.
Abstract (Originalsprache)
The threat of nuclear or radiological events requires early diagnostic tools for radiation induced health effects. Localized radiation injuries (LRI) are severe outcomes of such events, characterized by a latent presymptomatic phase followed by symptom onset ranging from erythema and edema to ulceration and tissue necrosis. Early diagnosis is crucial for effective triage and adapted treatment, potentially through minimally invasive biomarkers including circulating microRNAs (miRNAs), which have been correlated with tissue injuries and radiation exposure, suggesting their potential in diagnosing LRI. In this study, we sought to identify early miRNA signatures for LRI severity prognosis before clinical symptoms appear. Using a mouse model of hindlimb irradiation at 0, 20, 40, or 80 Gy previously shown to lead to localized injuries of different severities, we performed broad-spectrum plasma miRNA profiling at two latency stages (day 1 and 7 post-irradiation). The identified candidate miRNAs were then challenged using two independent mouse cohorts to refine miRNA signatures. Through sparse partial least square discriminant analysis (sPLS-DA), signatures of 14 and 16 plasma miRNAs segregated animals according to dose groups at day 1 and day 7, respectively. Interestingly, these signatures shared 9 miRNAs, including miR-19a-3p, miR-93-5p, miR-140-3p, previously associated with inflammation, radiation response and tissue damage. In addition, the Bayesian latent variable modeling confirmed significant correlations between these prognostic miRNA signatures and day 14 clinical and functional outcomes from unrelated mice. This study identified plasma miRNA signatures that might be used throughout the latency phase for the prognosis of LRI severity. These results suggest miRNA profiling could be a powerful tool for early LRI diagnosis, thereby improving patient management and treatment outcomes in radiological emergency situations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Autorité de Sûreté Nucléaire et de Radioprotection (ASNR), PSE-SANTE/SERAMED/LRAcc, Fontenay-aux-Roses, France.
- EDF, DPN, 1 place Pleyel, Saint Denis, France.
- ASNR, PSE-SANTE, Fontenay-aux-Roses, France.
ORCID-Profile: Jules Gueguen, Stéphane Flamant
Förderung
- Electricité de France
- Agence Nationale de la Recherche
Zitieren
APA
Ancel, L., Gueguen, J., Thoër, G., Marçais, J., Chemloul, A., Le Guen, B., Benderitter, M., Tamarat, R., Souidi, M., Benadjaoud, M. A., & Flamant, S. (2025). Presymptomatic microRNA-based biomarker signatures for the prognosis of localized radiation injury in mice. PLOS One. https://doi.org/10.1371/journal.pone.0329737
Vancouver
Ancel L, Gueguen J, Thoër G, Marçais J, Chemloul A, Le Guen B, et al. Presymptomatic microRNA-based biomarker signatures for the prognosis of localized radiation injury in mice. PLOS One. 2025. doi:10.1371/journal.pone.0329737
BibTeX
@article{Ancel2025,
author = {Ancel, Lucie and Gueguen, Jules and Thoër, Guillaume and Marçais, Jules and Chemloul, Aïda and Le Guen, Bernard and Benderitter, Marc and Tamarat, Radia and Souidi, Maâmar and Benadjaoud, Mohamed Amine and Flamant, Stéphane},
title = {Presymptomatic microRNA-based biomarker signatures for the prognosis of localized radiation injury in mice},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0329737}
}
EUVIMED